Ruxolitinib

Ruben A. Mesa, Uma Yasothan, Peter Kirkpatrick

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

Original languageEnglish (US)
Pages (from-to)103-104
Number of pages2
JournalNature Reviews Drug Discovery
Volume11
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Primary Myelofibrosis
Janus Kinases
Essential Thrombocythemia
Polycythemia Vera
United States Food and Drug Administration
INCB018424
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Mesa, R. A., Yasothan, U., & Kirkpatrick, P. (2012). Ruxolitinib. Nature Reviews Drug Discovery, 11(2), 103-104. https://doi.org/10.1038/nrd3652

Ruxolitinib. / Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter.

In: Nature Reviews Drug Discovery, Vol. 11, No. 2, 02.2012, p. 103-104.

Research output: Contribution to journalArticle

Mesa, RA, Yasothan, U & Kirkpatrick, P 2012, 'Ruxolitinib', Nature Reviews Drug Discovery, vol. 11, no. 2, pp. 103-104. https://doi.org/10.1038/nrd3652
Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nature Reviews Drug Discovery. 2012 Feb;11(2):103-104. https://doi.org/10.1038/nrd3652
Mesa, Ruben A. ; Yasothan, Uma ; Kirkpatrick, Peter. / Ruxolitinib. In: Nature Reviews Drug Discovery. 2012 ; Vol. 11, No. 2. pp. 103-104.
@article{402e14dac7b1416c91e04d7ae8264e28,
title = "Ruxolitinib",
abstract = "In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.",
author = "Mesa, {Ruben A.} and Uma Yasothan and Peter Kirkpatrick",
year = "2012",
month = "2",
doi = "10.1038/nrd3652",
language = "English (US)",
volume = "11",
pages = "103--104",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Ruxolitinib

AU - Mesa, Ruben A.

AU - Yasothan, Uma

AU - Kirkpatrick, Peter

PY - 2012/2

Y1 - 2012/2

N2 - In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

AB - In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

UR - http://www.scopus.com/inward/record.url?scp=84856509517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856509517&partnerID=8YFLogxK

U2 - 10.1038/nrd3652

DO - 10.1038/nrd3652

M3 - Article

C2 - 22293561

AN - SCOPUS:84856509517

VL - 11

SP - 103

EP - 104

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 2

ER -